{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"ORR is the proportion of patients with a Complete Response (CR) or Partial Response (PR) via independently reviewed RECIST v 1.1 relative to the total number of patients in the mITT population.","groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T cells. Prior to dosing, participants had to remain eligible and, prior to dosing, were given lymphodepleting chemotherapy (fludarabine and cyclophosphamide). Six (6) participants were dosed once with a mean total of 50.7 x 10\\^7 TC-510 T cells (mITT population). All subjects completed the interventional phase of the trial.","id":"OG000","title":"Phase 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The modified ITT Population included all participants enrolled and treated with TC-510.","reportingStatus":"POSTED","timeFrame":"From first TC-510 infusion through study completion (up to approximately 38 months)","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}